

Severe Vascular Complications Following Thrombolytic Therapy in a Case of Prosthetic Mitral Valve Thrombosis – A Case Report

Ayan Husain¹, Shilpa Abhay Gaidhane², Priti Abhay Karadbhajane³, Sourya Acharya⁴, Apoorva Nirmal⁵

^{1, 2, 3, 4, 5} Department of Medicine, Jawaharlal Nehru Medical College, DMIMS (Deemed to Be University), Sawangi (Meghe), Wardha, Maharashtra, India.

INTRODUCTION

Prosthetic cardiac valve thrombosis is a rare but dangerous complication;^{1,2} particularly in patients with low conformity on anticoagulant therapy. Thromboembolic problems happen after mechanical valve substitution in 0.5 - 8 percent.³⁻⁵ Fibrinolytic therapy to treat the thrombosis is widely used nowadays with high efficacy and no severe side effects as compared to emergency surgical treatment, which is associated with high mortality.⁶

Surgical valve repair in patients with rheumatic heart disease remains the gold standard for the treatment. Thrombosis of the prosthetic heart valve in patients undergoing valve replacement, is the most severe and deadly complication. Currently, the treatments available for symptomatic prosthetic valve thrombosis are immediate surgery or thrombolytic therapy (TT). In rural hospital settings patients are poor and there is a lack of surgical expertise. These factors make TT the perfect treatment for prosthetic valve thrombosis. But one should be aware of embolic complications.

PRESENTATION OF CASE

A 30-year-old male patient a known case of rheumatic heart disease with severe mitral stenosis underwent mitral valve replacement with TTK Chitra mitral prosthesis in 2017. Two years later, he presented to the Emergency Department of Medicine at night 8 pm with complaints of, sudden onset of breathlessness, chest pain and orthopnoea for 24 hours. He had stopped taking anticoagulants a month back due to financial constraints.

On examination, heart rate - 115 / min, BP - 86 / 50 mmHg, jugular venous pressure (JVP) raised. Metallic click could not be heard, bilateral crepitations present. Electrocardiogram-atrial fibrillation (ECG-AF) with FVR with right ventricular hypertrophy. Haemoglobin (Hb) - 14.6 g / dl, white blood cell (WBC) - 13900 / mm,³ platelets - 1.56 lac / mm,³ creatinine - 1.1, liver function test (LFT) normal and international normalised ratio (INR) 1.08. Blood cultures showed no growth of any organisms. Clinical diagnosis of a thrombotic mitral valve thrombosis was confirmed by transthoracic echocardiography. The effective valve area was 0.45 cm² with evidence of 1cm² thrombus and an increased mean peak gradient (23 mmHg) across the mitral valve (Figure 1).

Corresponding Author:

*Dr. Shilpa Gaidhane,
Department of Medicine,
Jawaharlal Nehru Medical College,
DMIMS (Deemed to Be University),
Sawangi (Meghe), Wardha,
Maharashtra, India.
E-mail: drshilpagaidhane@gmail.com*

DOI: 10.14260/jemds/2021/221

How to Cite This Article:

Husain A, Gaidhane SA, Karadbhajane PA, et al. Severe vascular complications following thrombolytic therapy in a case of prosthetic mitral valve thrombosis – a case report. J Evolution Med Dent Sci 2021;10(14):1035-1038, DOI: 10.14260/jemds/2021/221

*Submission 02-11-2020,
Peer Review 11-02-2021,
Acceptance 17-02-2021,
Published 05-04-2021.*

Copyright © 2021 JEMDS. This is an open access article distributed under Creative Commons Attribution License [Attribution 4.0 International (CC BY 4.0)]




Figure 1.
2D-ECHO Showing Echogenic Shadows Over Mitral Valve with Increased Mean Peak Gradient Across It




Figure 2.
Peripheral Angiography Showing Bilateral Obstructed Common Femoral Arteries by a Saddle Thrombus at Aortic Bifurcation




Figure 3.
Blackening of Left Lower Limb Digits



Figure 4.
Peripheral Angiography Post Embolectomy Showing Patency of Right Lower Limb Arteries




Figure 5.
Peripheral Angiography Post Embolectomy Showing Non-Patency and Thrombus in Left Distal Superficial Femoral Artery

Therefore, dobutamine along with furosemide were infused continuously for cardiogenic shock and acute pulmonary oedema, and intravenous diltiazem was given for heart rate control. Fibrinolytic therapy with streptokinase was given because of the unavailability of vascular surgeon at the time of presentation. Within 3 hours after the start of therapy the patient's symptoms of heart failure had improved markedly but he developed pain and weakness of both lower limbs, more in left side as compared to right side. Peripheral pulsations could not be palpated in both the lower limbs below the femoral artery. 2D-ECHO post thrombolysis-good leaflet motion of mitral valve and peak gradient of 8 mmHg across the valve with no thrombus or vegetation. The calculated mitral valve area increased to 1.65 cm.² Bilateral lower limb angiography was done immediately which showed saddle thrombus at aortic bifurcation. (Figure 2) with slow reformation of bilateral iliac arteries. Thrombectomy was done by the vascular surgeon at our institute and parenteral anticoagulants were started.

After three days, right lower limb symptoms resolved. But only partial relief of symptoms in left lower limb and there was left sided foot drop after 5 - 6 days, the patient started developing blackening of left lower limbs digits without any clear-cut line of demarcation. (Figure 3). Check angiography revealed no saddle thrombus at aortic bifurcation, good distal flow in right common iliac artery and below (Figure 4) but there was long segment subacute thrombus in left distal superficial femoral artery (Figure 5). There was no gangrene and the pain decreased. Patient was managed conservatively, and he was discharged on oral anticoagulants, antiplatelets and analgesics. Followed up with us one month later. The blackening of digits had recovered. Doppler showed partial thrombotic narrowing of superficial femoral artery with good collateral circulation.

Factors Deciding	Thrombolytic Therapy	Surgery
Clinical features	High surgical risk, NYHA class I to II, no contraindication to fibrinolysis, first episode of valve thrombosis	Low surgical risk, NYHA class III to IV, contraindication to fibrinolysis, recurrent valve thrombosis
Concurrent indications	No need for other cardiac surgery such as CABG or other valve disease	Coronary artery disease needing CABG, concomitant valve or aortic disease requiring surgery
Imaging findings	Thrombus or small clot (< 1 cm ²), no left atrial thrombus	Large clot (> 1 cm ²), mobile thrombus > 0.3 cm in diameter, or left atrial thrombus
Resources	No surgical expertise required	Surgical expertise is required

Table 1. Factors Deciding Thrombotic Therapy vs. Surgery

DISCUSSION OF MANAGEMENT

Prosthetic valve thrombosis (PVT) is a very serious complication after valve replacement. Factors predisposing to thrombosis include atrial fibrillation, sub-therapeutic anticoagulation and irregular INR monitoring, and pregnancy. Mitral valve is approximately twice as commonly involved as aortic valve.^{1,2} The most common complications of PVT are valvular obstruction or stenosis and thromboembolism. The reported incidence of symptomatic obstructive mechanical PVT ranges from 0.2 to 8 % per year in India and it is more common (6 %) in patients receiving sub-therapeutic anticoagulation.³⁻⁵ The rate of thromboembolism after PVT during the first 6 months is significantly more and it is highest during the first 30 days.⁶⁻⁸ The risk of thromboembolism is least in patients with bio-prosthetic valves (who are generally not anti-coagulated), higher with patients of mechanical valves who are anticoagulated and highest in patients of mechanical valves receiving inadequate anti-coagulation.⁹ High mortality and morbidity are associated with prosthetic valve thrombosis.¹⁰

Prosthetic valve thrombosis has been split into two forms: obstructive (embolus of more than 10 mm²) and non-obstructive (embolus of less than 10 mm²) prosthetic valve thrombosis and their therapeutic approach.¹⁰

Valvular obstruction may present with heart failure, presyncope or syncope and in rare cases sudden cardiac death. Left sided PVT may cause systemic embolic complications such as stroke, peripheral gangrene or less frequently myocardial infarction. Right sided PVT can complicate into pulmonary embolism and rarely systemic embolic events via paradoxical embolism.¹¹

The diagnostic criteria on echo cardiac for PVT are decreased valve strength, mass over the valve (thrombus), decreased effective prosthetic area, and trans prosthetic valve flow, prosthetic valve incompetence, increased trans-prosthetic gradients.¹² Treatment modality depends on i) existence of distortion of the valve, ii) Medical status of the patient, iii) the thrombus size, iv) The local level of medicine and economy, and v) the experience with reoperation. Hospitals that do not have practice with reoperation or location of financially poor regions have a high surgical cost, making TT the perfect treatment for PVT.¹³

Mechanical PVT is managed mainly by fibrinolysis or by surgery (thrombectomy and valve replacement) along with supportive treatment of heart failure and anticoagulation with unfractionated heparin (Table 1).¹ In our case thrombolysis was preferred due to high New York Heart Association (NYHA) Class, and un-availability of surgeon and expertise with reopening in emergency hours. We ruled out the contraindications for thrombolysis¹. There was uncontrolled blood pressure hypertension above 180 / 110 mmHg; ischaemic stroke or cerebral haemorrhage within half a year; intracranial tumour; active internal bleeding in the last 4 weeks; possible aortic dissection; past of previous 3 weeks for major surgery; 2 week's large uncompressible artery puncture; antenatal status; active stomach ulcers; and history of major surgery in the last 3 weeks, patients with a thrombus size > 1 cm² or a high density of thrombi were also excluded.¹³ Recently, as the first-line treatment plan for class 1-B

indications, the 2017 American Heart Association (AHA)/ American College of Cardiology (ACC), based update of the 2014 AHA / ACC instruction for the treatment of patients with valvular heart disease advised using slow-infusion low-dose TT or immediate surgery for obstructive PVT.¹⁴

Complications of thrombolysis in PVT include major bleeding intracerebral, systemic embolism, recurrent PVT, and death.^{15,16} Surgery is recommended for vital surgery for obstructive thrombosis (thrombus more than one cm²) or fibrinolytic therapy for non-obstructive PVT (approximately 10 mm).¹⁵ In seven PVT thrombolysis trials, Karthikeyan tested 690 patients and observed no substantial contrast in main results (development in gradient transvalvular pressure and severe problems) between surgery and thrombolysis. They indicated, however, that an immediate surgical operation is preferable to TT in an experienced centre.¹² Previous data revealed that 69 percent death rate for surgery was higher compared with this meta-analysis, while the recorded mortality rate for TT was as high as 16 percent, relying on the NYHA grade and the priority of the surgery.¹³ Therefore, suitability of surgical treatment is not for all patients. In a meta-analysis by Cáceres-Lórigal recorded 4.6 to 12.8 percent rate of embolism complications from nine studies of 413 patients¹³

Major risk factors for complications of thrombolysis include NYHA class III or IV and a large thrombus. The risk of systemic embolism, bleeding and death are the complications of high-dose fibrinolytic therapies. Bleeding during fibrinolysis is rare in the absence of bleeding conditions like pregnancy, postoperative, or pericarditis.¹⁴

Maintenance of anticoagulation therapy with INR monitoring is the corner stone for prevention of thrombus formation among patients with prosthetic valve replacement.²¹ More efforts are need for patient education and drug adherence of anticoagulation therapy.²²

CONCLUSIONS

Thrombolysis for prosthetic valve thrombosis is a good alternative to surgery in selected patients at a tertiary care hospital without emergency facility of vascular-surgical and Cath lab facility. Physicians should be aware of embolic complications to manage them successfully. Adherence to anticoagulants and monitoring of INR is the key to prevent prosthetic valve thrombosis.

Financial or other competing interests: None.

Disclosure forms provided by the authors are available with the full text of this article at jemds.com.

REFERENCES

- [1] Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. *Heart* 2007;93(1):137-42.
- [2] Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. *Circulation* 1994;89(2):635-41.

- [3] Inamdar A, Shende SP, Inamdar S. Prosthetic valve obstruction: redo surgery or fibrinolysis? *Medical Journal of Dr. DY Patil University* 2017;10(3):246-50.
- [4] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(Suppl 2):e419S-96S.
- [5] Dürrleman N, Pellerin M, Bouchard D, et al. Prosthetic valve thrombosis: twenty-year experience at the montreal heart institute. *J Thorac Cardiovasc Surg* 2004;127(5):1388-92.
- [6] Deviri E, Sareli P, Wisenbaugh T, et al. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. *J Am Coll Cardiol* 1991;17(3):646-50.
- [7] Puvimanasinghe JP, Steyerberg EW, Takkenberg JJ, et al. Prognosis after aortic valve replacement with a bioprosthesis: predictions based on meta-analysis and microsimulation. *Circulation* 2001;103(11):1535-41.
- [8] Remadi JP, Baron O, Roussel C, et al. Isolated mitral valve replacement with St. Jude Medical prosthesis: long-term results: a follow-up of 19 years. *Circulation* 2001;103(11):1542-5.
- [9] Le Tourneau T, Lim V, Inamo J, et al. Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study. *Chest* 2009;136(6):1503-13.
- [10] Karakurt A, Başbuğ HS. Prosthetic heart valve thrombosis treated with low-dose slow-infusion fibrinolytic therapy. *J Cardiol Cases* 2015;12(1):12-5.
- [11] Faria DC, Roque D, Santos M, et al. Obstructive mechanical mitral valve thrombosis: a case report. *Annals of Clinical Case Reports* 2019;4:1655.
- [12] Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. *Eur Heart J* 2013;34(21):1557-66.
- [13] Cáceres-Lóriga FM, Morais H. Thrombotic obstruction in left-side prosthetic valves: role of thrombolytic therapy. *Indian Heart J* 2015;67(Suppl 2):S10-2.
- [14] Matiasz R, Rigolin VH. 2017 Focused update for management of patients with valvular heart disease: summary of new recommendations. *Journal of the American Heart Association* 2018;7(1):e007596.
- [15] Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. *J Am Coll Cardiol* 2003;41(4):653-8.
- [16] Huang G, Schaff HV, Sundt TM, et al. Treatment of obstructive thrombosed prosthetic heart valve. *J Am Coll Cardiol* 2013;62(19):1731-6.
- [17] Srivastava R, Showkat HI, Kumar V, et al. An interesting case of stuck mitral valve by clot, post thrombolysis developed acute right limb ischemia treated with local catheter directed re-thrombolysis successfully. *Int J Cardiol Cardiovasc Res* 2018;4(2):085-8.
- [18] Hirschl MM, Gwechenberger M, Zehetgruber M, et al. Severe complications following thrombolytic therapy of an acute thrombosis of a prosthetic mitral valve. *Clin Investig* 1994;72(6):466-9.
- [19] Bagheri RK, Keihanian F, Ahmadi M, et al. Successful treatment of prosthetic pulmonary valve thrombosis with reteplase: a case report. *Int Med Case Rep J* 2018;11:205-8.
- [20] Shi J, Bai ZX, Hu J, et al. Rare early prosthesis obstruction after mitral valve replacement: a case report and literature review. *J Cardiothorac Surg* 2012;7:64.
- [21] Gazi E, Altun B, Temiz A, et al. Successful thrombolytic treatment of prosthetic mitral valve thrombosis. *BMJ Case Rep* 2013;2013:bcr2013009917.
- [22] Özkan M, Çakal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. *Circulation* 2013;128(5):532-40.